Sign In
NASDAQ:IRWD
Ironwood Pharmaceuticals Stock Earnings Reports
$0.775
+0.0551 (+7.66%)
At Close: Apr 23, 2025
Ironwood Pharmaceuticals Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | - |
| Revenue estimate | 66.767M |
| Revenue actual | - |
| Expected change | +/- 11.45% |
Q4 2024
Missed
$0.0200 (-80.00%)
| Release date | Feb 27, 2025 |
| EPS estimate | $0.100 |
| EPS actual | $0.0200 |
| EPS Surprise | -80.00% |
| Revenue estimate | 67.02M |
| Revenue actual | 90.545M |
| Revenue Surprise | 35.10% |
Q3 2024
Missed
$0.0200 (-75.00%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.0800 |
| EPS actual | $0.0200 |
| EPS Surprise | -75.00% |
| Revenue estimate | 92.48M |
| Revenue actual | 91.592M |
| Revenue Surprise | -0.96% |
Q2 2024
Missed
-$0.0054 (-103.61%)
| Release date | Aug 08, 2024 |
| EPS estimate | $0.150 |
| EPS actual | -$0.0054 |
| EPS Surprise | -103.61% |
| Revenue estimate | 107M |
| Revenue actual | 94.396M |
| Revenue Surprise | -11.78% |
Last 4 Quarters for Ironwood Pharmaceuticals
Below you can see how IRWD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $4.05 |
| EPS estimate | $0.150 |
| EPS actual | -$0.0054 |
| EPS surprise | -103.61% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $6.53 |
| Aug 05, 2024 | $6.20 |
| Aug 06, 2024 | $6.07 |
| Aug 07, 2024 | $6.01 |
| Aug 08, 2024 | $4.05 |
| Aug 09, 2024 | $4.24 |
| Aug 12, 2024 | $4.24 |
| Aug 13, 2024 | $4.49 |
| Aug 14, 2024 | $4.34 |
| 4 days before | -37.98% |
| 4 days after | 7.16% |
| On release day | 4.69% |
| Change in period | -33.54% |
Q3 2024
Missed
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $4.66 |
| EPS estimate | $0.0800 |
| EPS actual | $0.0200 |
| EPS surprise | -75.00% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $4.19 |
| Nov 04, 2024 | $4.19 |
| Nov 05, 2024 | $4.49 |
| Nov 06, 2024 | $5.04 |
| Nov 07, 2024 | $4.66 |
| Nov 08, 2024 | $4.96 |
| Nov 11, 2024 | $4.78 |
| Nov 12, 2024 | $4.39 |
| Nov 13, 2024 | $4.31 |
| 4 days before | 11.22% |
| 4 days after | -7.51% |
| On release day | 6.44% |
| Change in period | 2.86% |
Q4 2024
Missed
| Release date | Feb 27, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $1.62 |
| EPS estimate | $0.100 |
| EPS actual | $0.0200 |
| EPS surprise | -80.00% |
| Date | Price |
|---|---|
| Feb 21, 2025 | $1.82 |
| Feb 24, 2025 | $1.80 |
| Feb 25, 2025 | $1.74 |
| Feb 26, 2025 | $1.71 |
| Feb 27, 2025 | $1.62 |
| Feb 28, 2025 | $1.61 |
| Mar 03, 2025 | $1.52 |
| Mar 04, 2025 | $1.49 |
| Mar 05, 2025 | $1.54 |
| 4 days before | -10.74% |
| 4 days after | -4.94% |
| On release day | -0.617% |
| Change in period | -15.15% |
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | -$0.0200 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 16, 2025 | $0.750 |
| Apr 17, 2025 | $0.727 |
| Apr 21, 2025 | $0.705 |
| Apr 22, 2025 | $0.719 |
| Apr 23, 2025 | $0.775 |
Ironwood Pharmaceuticals Earnings Call Transcript Summary of Q4 2024
Focus on Apraglutide:
- Ironwood is prioritizing the advancement of apraglutide, a long-acting GLP-2 therapy intended for patients with short bowel syndrome (SBS) reliant on parenteral support.
- Recent clinical data indicates that 27 patients achieved enteral autonomy, highlighting the potential of apraglutide to significantly impact patient care.
NDA Submission:
- The rolling submission of the New Drug Application (NDA) for apraglutide has begun, with expected completion in Q3 2025. If approved, it will be the first weekly GLP-2 treatment for SBS.
LINZESS Performance:
- LINZESS (for IBS-C and chronic constipation) continues to perform strongly, with a 12% increase in prescription demand in Q4 2024 year-over-year. Investors should keep an eye on the upcoming NDA submission and ongoing financial performance as the company navigates pricing pressures from Medicare changes and manages its debt effectively.
Ironwood Pharmaceuticals Earnings History
Earnings Calendar
FAQ
When is the earnings report for IRWD?
Ironwood Pharmaceuticals (IRWD) has scheduled its earnings report for May 08, 2025 before the markets open.
What is the IRWD price-to-earnings (P/E) ratio?
IRWD P/E ratio as of Apr 23, 2025 (TTM) is 3.98.
What is the IRWD EPS forecast?
The forecasted EPS (Earnings Per Share) for Ironwood Pharmaceuticals (IRWD) for the first fiscal quarter 2025 is -$0.0200.
What are Ironwood Pharmaceuticals's retained earnings?
On its balance sheet, Ironwood Pharmaceuticals reported retained earnings of $90.55 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
